JOHANNESBURG, March 29 (Xinhua) — Medicine regulator South African Health Products Regulatory Authority (SAHPRA) on Monday said the Ivermectin was not authorized to be prescribed for treatment of COVID-19.
SAHPRA released a statement after the national broadcaster South African Broadcasting Corporation reported that SAHPRA have given a greenlight for Ivermectin to treat COVID-19.
“This is grossly untrue, misleading to the public and irresponsible and could have dire consequences,” read the statement.
“The position of SAHPRA remains steadfast. Ivermectin may be prescribed and dispensed to patients without awaiting Section 21 authorisation, but is still subject to receiving section 21 authorization, informed consent and all reporting requirements normally required under Section 21,” said the regulator.
SAHPRA explained that they have registered Soolantra cream, of which the active ingredient is Ivermectin, for topical treatment of moderate to severe inflammatory lesions of papulopustular rosacea in adult patients. However, the cream is not for the prevention or treatment of COVID-19.
“Unregistered Ivermectin-containing finished pharmaceutical products may only be accessed under SAHPRA’s Ivermectin Controlled Compassionate Use Program Guideline through the authorized suppliers of such products,” said the regulator. Enditem